Literature DB >> 20162282

Hemodynamic effects of combined therapy using partial splenic embolization and transjugular retrograde obliteration for gastric varices with gastrorenal shunt.

Fumio Chikamori1, Atsushi Inoue, Hiroshi Okamoto, Nobutoshi Kuniyoshi, Takahiko Kawashima, Yasuhiro Takase.   

Abstract

BACKGROUND: The purpose of the present study was to investigate the short-term effects of combined therapy using partial splenic embolization (PSE) and transjugular retrograde obliteration (TJO) on the portal hemodynamics of gastric varices with a gastrorenal shunt. PATIENTS AND METHODS: Sixteen patients with gastric varices and a gastrorenal shunt were included in this study. Partial splenic embolization was applied 2 weeks before TJO. The portal blood flow was measured by an ultrasonic duplex Doppler system, and the wedged hepatic venous pressure (WHVP) was measured by hepatic venous catheterization, before and after the combined therapy.
RESULTS: The complete obliteration of the gastrorenal shunt and gastric varices was revealed by retrograde shuntography and computed tomography after TJO in all cases. The WHVP before and just after PSE was 23 +/- 7 and 19 +/- 7 mmHg, respectively, showing a significant change (P < 0.01). The WHVP before and the day after TJO was 20 +/- 5 mmHg and 22 +/- 6 mmHg, respectively, showing a significant change (P < 0.01). There was no significant difference between the WHVP before and after the combined therapy. The portal venous flow volume before and after the combined therapy were 514 +/- 146 and 512 +/- 161 ml/min, respectively, showing no significant change. However, the splenic venous flow volume before and after the combined therapy was 319 +/- 131 and 179 +/- 113 ml/min, respectively, showing a significant change (P < 0.05).
CONCLUSIONS: The WHVP did not change after the combined therapy of PSE and TJO. Partial splenic embolization contributed to protecting portal congestion after TJO. We conclude that the combined therapy using PSE and TJO is an effective treatment for gastric varices from the portal hemodynamic point of view.

Entities:  

Mesh:

Year:  2010        PMID: 20162282     DOI: 10.1007/s00268-010-0451-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  18 in total

1.  Long term follow-up for patients with liver cirrhosis after partial splenic embolization.

Authors:  K Murata; K Shiraki; K Takase; T Nakano; Y Tameda
Journal:  Hepatogastroenterology       Date:  1996 Sep-Oct

2.  Effect of liver transplantation on spleen size, collateral veins, and platelet counts.

Authors:  Fumio Chikamori; Seigo Nishida; Gennaro Selvaggi; Panagiotis Tryphonopoulos; Jang I Moon; David M Levi; Tomoaki Kato; Eddie R Island; Akira Maki; Akin Tekin; Andreas G Tzakis
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

3.  Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration.

Authors:  H Kanagawa; S Mima; H Kouyama; K Gotoh; T Uchida; K Okuda
Journal:  J Gastroenterol Hepatol       Date:  1996-01       Impact factor: 4.029

4.  Transjugular retrograde obliteration for gastric varices.

Authors:  F Chikamori; S Shibuya; Y Takase; A Ozaki; K Fukao
Journal:  Abdom Imaging       Date:  1996 Jul-Aug

5.  Endoscopic classification of gastric varices.

Authors:  M Hashizume; S Kitano; H Yamaga; N Koyanagi; K Sugimachi
Journal:  Gastrointest Endosc       Date:  1990 May-Jun       Impact factor: 9.427

6.  Portal hemodynamics in patients with gastric varices. A study in 230 patients with esophageal and/or gastric varices using portal vein catheterization.

Authors:  K Watanabe; K Kimura; S Matsutani; M Ohto; K Okuda
Journal:  Gastroenterology       Date:  1988-08       Impact factor: 22.682

7.  Correlation between endoscopic and angiographic findings in patients with esophageal and isolated gastric varices.

Authors:  F Chikamori; N Kuniyoshi; S Shibuya; Y Takase
Journal:  Dig Surg       Date:  2001       Impact factor: 2.588

8.  Gastroesophageal decongestion and splenectomy in the treatment of esophageal varices in bilharzial cirrhosis: further studies with a report on 355 operations.

Authors:  M A Hassab
Journal:  Surgery       Date:  1967-02       Impact factor: 3.982

9.  Partial splenic embolization: long-term outcome.

Authors:  Birger Pålsson; Magnus Hallén; Annika Mandahl Forsberg; Anders Alwmark
Journal:  Langenbecks Arch Surg       Date:  2003-01-15       Impact factor: 3.445

10.  Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis.

Authors:  Takashi Tajiri; Masahiko Onda; Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Tatsuo Kumazaki
Journal:  Hepatogastroenterology       Date:  2002 Sep-Oct
View more
  4 in total

1.  Comparison of TIPS alone and combined with partial splenic embolization (PSE) for the management of variceal bleeding.

Authors:  Yue-Meng Wan; Yu-Hua Li; Zhi-Yuan Xu; Hua-Mei Wu; Xi-Nan Wu; Ying Xu
Journal:  Eur Radiol       Date:  2019-02-22       Impact factor: 5.315

2.  Causes of peripheral cytopenia in hepatitic cirrhosis and portal hypertensive splenomegaly.

Authors:  Yunfu Lv; Wan Yee Lau; Hongfei Wu; XiaoYu Han; Xiaoguang Gong; Ning Liu; Jie Yue; Qingqing Li; YeJuan Li; Jie Deng
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

3.  Impact of total splenectomy on peripheral lymphocytes and their subsets in patients with hypersplenism associated with cirrhotic portal hypertension.

Authors:  Yunfu Lv; Hongfei Wu; Wan Yee Lau; Jinfang Zheng; Jincai Wu; Min Zeng
Journal:  Sci Rep       Date:  2021-10-28       Impact factor: 4.379

4.  Left Gastric Vein Width Is an Important Risk Factor for Exacerbation of Esophageal Varices Post Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices in Cirrhotic Patients.

Authors:  Taku Mizutani; Kazushige Nirei; Tatsuo Kanda; Masayuki Honda; Tomotaka Ishii; Shuhei Arima; Yoichiro Yamana; Naoki Matsumoto; Shunichi Matsuoka; Mitsuhiko Moriyama
Journal:  Medicina (Kaunas)       Date:  2022-01-28       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.